For any media enquiries,
Please contact email@example.com or Rakhee on +44 (0) 7944 865985, Mike on +44 (0) 7802 196766 or Brad on +44 (0) 7375 558517.
Stabilitech Biopharma earns prestigious position on WHO list of vaccine developers
Burgess Hill, UK, 11 May 2020 STABILITECH BIOPHARMA LTD (“Stabilitech”), a UK biotechnology company developing next generation vaccines and biopharmaceuticals, announces today that, they have been recognised on a global level by the World Health Organisation (WHO) as a vaccine developer. Read more
Stabilitech Biopharma strengthens leadership team, as Jeffrey Almond joins the board in race to develop oral vaccine for COVID-19
Burgess Hill, UK, 07 May 2020 STABILITECH BIOPHARMA LTD (“Stabilitech”), a UK biotechnology company developing next generation vaccines and biopharmaceuticals, has today announced that Professor Jeffrey Almond will be joining the board as they step up their efforts in search of a vaccine for COVID-19. Read more
Stabilitech Biopharma joins race to develop COVID-19 vaccine delivering unique double immunity using self-administered capsules
Burgess Hill, UK, 30 April 2020 STABILITECH BIOPHARMA LTD (“Stabilitech”), a UK biotechnology company developing next generation vaccines and biopharmaceuticals, has announced today that, it is seeking an investment of £6m to fund clinical trials and manufacturing of an oral coronavirus vaccine, OraPro-COVID-19. Read more
Stabilitech in the media
The Washington Post
London will Führung bei Corona-Impfstoff übernehmen – 01/06/2020
The Wall Street Journal
The Daily Express
Virus-stung UK banks on vaccine drive – 22/05/2020
Tonight – The Race for a Cure: Making Britain Safe – 21/05/2020
Genetic Engineering & Biotechnology News
COVID-19 candidates: Stabilitech Biopharma – 19/05/2020
The Daily Telegraph
Britain in coronavirus lockdown, in pictures – 19/05/2020
Business Insider Italia
Los Angeles Times
Biopharma update on the Novel Coronavirus: April 30 – 30/04/2020
The Pharma Letter
Other news to note for April 30, 2020 – 30/04/2020
CNBC NEWS – USA
USA LIFE SCIENCES DATABASE
EPR – EUROPEAN PHARMACEUTICAL REVIEW
- Millions of people infected.
- Billions of people affected.
- Trillions of dollars invested.
The world is fighting back.
Stabilitech is part of that fight – you can be too.
The OraPro-COVID-19. A coronavirus vaccine that delivers double immunity via a capsule that may be delivered by post that can be swallowed. No needles, no doctors or nurses, no queues for a vaccine, no risk of cross infection.
The Los Angeles Times’ Ralph Vartabedian says:
“The company has taken a harmless virus common in the human body and modified its genetic structure to include two genes that are responsible for the now famous spikes in the coronavirus. It is formulated into a pill that, when digested, would prompt the immune system to produce antibodies to attack the coronavirus spikes. The approach requires small amounts of the drug, meaning it would be easier to manufacture for universal consumption.”
Thermally stable, self-administered vaccines in capsule form are the future